- Ibudilast
-
- $1.00 / 1g
-
2025-04-23
- CAS:50847-11-5
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 100kg
- Ibudilast
-
- $0.00 / 10g
-
2025-04-23
- CAS:50847-11-5
- Min. Order: 1g
- Purity: 99% HPLC
- Supply Ability: 10000
- Ibudilast
-
- $0.00 / 1Kg/Bag
-
2025-04-23
- CAS:50847-11-5
- Min. Order: 100g
- Purity: 99%min
- Supply Ability: 50kg
|
| | Ibudilast Basic information |
| | Ibudilast Chemical Properties |
| Melting point | 53-54°C | | Boiling point | 175°C/7.5mmHg(lit.) | | density | 1.09 | | refractive index | 1.5500 (estimate) | | storage temp. | Sealed in dry,2-8°C | | solubility | DMSO: 28 mg/mL, soluble | | form | solid | | pka | 1.22±0.30(Predicted) | | color | white | | Merck | 14,4879 | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. | | InChI | InChI=1S/C14H18N2O/c1-9(2)13-12(14(17)10(3)4)11-7-5-6-8-16(11)15-13/h5-10H,1-4H3 | | InChIKey | ZJVFLBOZORBYFE-UHFFFAOYSA-N | | SMILES | C(C1=C2N(N=C1C(C)C)C=CC=C2)(=O)C(C)C | | CAS DataBase Reference | 50847-11-5(CAS DataBase Reference) |
| Hazard Codes | Xn | | Risk Statements | 22-36/37/38 | | Safety Statements | 26-36 | | WGK Germany | 3 | | RTECS | UR0711200 | | HS Code | 2933.99.8290 | | Toxicity | LD50 i.v. in mice: 260 mg/kg (Irikura, 1973) |
| | Ibudilast Usage And Synthesis |
| Description | Ibudilast is a leukomene antagonist and phosphodiesterase inhibitor useful in the
treatment of bronchial asthma. It antagonizes leukotriene D4-induced contractions of
guinea pig ileum and tracheal muscles in virro, and inhibits eosinophil accumulation in
vivo. | | Chemical Properties | White Solid | | Originator | Kyorin (Japan) | | Uses | a phosphodiesterase inhibitor with anti-inflammatory activity | | Uses | A leukotriene D4 antagonist. Used as an antiallergic, antiasthmatic, and vasodilator (cerebral) | | Uses | Inhibitors of phosphodiesterase 4 (PDE4), which catalyzes the hydrolysis of cAMP, have potential applications in a variety of diseases, including asthma. Ibudilast is an inhibitor of PDE4 (IC50 = 54-239 nM) that, at higher doses, also inhibits PDE3 and PDE5 (IC50 = 1,600-3,510 nM). Through this action, it suppresses the elaboration of mediators involved in asthma and inflammation.[Cayman Chemical] | | Definition | ChEBI: Ibudilast is a pyrazolopyridine. | | Brand name | Ketas | | Biological Activity | Phosphodiesterase inhibitor (IC 50 values are 53, 35, 48, 12 and 10 mM for PDE Ia, II, III, IV and V respectively). Inhibits platelet aggregation and is an orally-active cerebral vasodilator, bronchodilator and antiallergic agent. | | Biochem/physiol Actions | Phosphodiesterase IV (PDE4) inhbitor. Inhibits platelet aggregation. Anti-asthma drug. | | in vitro | ibudilast could potently inhibit purified human pde4a, 4b, 4c and 4d with ic50 values at 54, 65, 239 and 166 nm, respectively. ibudilast was also able to effectively block lps-induced tumor necrosis factor and n-formyl-metleu-phe-induced leukotriene b4 biosynthesis in human whole blood [1]. | | in vivo | rats received a daily oral administration of 10, 30 or 60 mg/kg ibudilast. results showed that in the vehicle-treated animals, white matter lesions and microglial activation occurred in the optic tract, internal capsule and corpus callosum. a low dose of ibudilast failed to suppress the white matter lesions and microglial activation, whereas a dose of either 30 or 60 mg/kg ibudilast ameliorated these lesions [2]. | | IC 50 | 54-239 nm | | storage | Store at RT | | References | 1) Kishi et al. (2001), Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall; Cardiovasc. Drug Rev., 19 215
2) Yamazaki et al. (2011), Ibudilast. A mixed PDE3/4 inhibitor, causes a selective and nitric oxide/cGMP-independent relaxation of the intracranial vertebrobasilar artery; Eur. J. Pharmacol., 650 605
3) Cueva Vargas et al. (2016), The glial cell modulator ibudilast attenuates neuroinflammation and enhances retinal ganglion cell viability in glaucoma through protein kinase A signaling.; Neurobiol. Dis., 93 156
4) Mizuno et al. (2004), Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia; Neuropharmacology, 46 404
5) Ledeboer et al. (2007), Ibudilast (AV-411). A class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes; Expert. Opin. Investig. Drugs, 16 935 |
| | Ibudilast Preparation Products And Raw materials |
|